Teva Moves Toward Biogenerics Goal With CoGenesys Acquisition
Israeli generics maker pays $400 million for the biopharma, which brings an advanced drug development platform called Albumin Fusion.
Israeli generics maker pays $400 million for the biopharma, which brings an advanced drug development platform called Albumin Fusion.